Stayble Therapeutics AB starts development of a new clinical indication and decides on a rights issue of approximately MSEK 35.2
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. Stayble Therapeutics AB, (”Stayble” or ”the Company”) announces that the Board of Directors has resolved